Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
Active Date:
October 01, 2019
IRB Number:
LU005
Condition/Disease:
Lung Cancer
Lead Researcher:
Brian Myre, MD
Location:
Edward Cancer Center - Naperville
Purpose:
This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.
Sponsor: NRG Oncology
https://clinicaltrials.gov/ct2/show/NCT03811002
Eligibility:
Patients with a pleural effusion will be eligible if thoracentesis is negative and non-bloody or if pleural fluid is too small to effectively sample
Not pregnant
No metastatic disease
No surgical resection of small cell lung cancer
No prior invasive malignancy unless disease free for a minimum of 2 years
No more than 1 cycle of platinum-based chemotherapy for SCLC or prior radiotherapy to the lungs or mediastinum prior to enrollment
No severe, active co-morbidity
Status:
Accepting Participants
Current Trial Type:
Interventional
Phase:
II/III
Contact Name:
Meribeth Siatta, MSN
Phone:
331-221-2162
Fax:
630-646-6074
Alternate Phone:
630-646-6072